Vipadenant clinical trials
Also written BIIB014.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses vipadenant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BIIB014
- 3
Studies by the year they started
4 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2009 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses vipadenant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and MidazolamCompletedPhase 1BiogenNCT01017666Written as BIIB014How we know
- BIIB014 Phase 2a MonotherapyWithdrawnPhase 2BiogenNCT00451815Written as active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.How we know
- BIIB014 Cardiovascular Monitoring StudyCompletedPhase 1BiogenNCT01035515Written as BIIB014 50mgHow we know
- Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's DiseaseCompletedPhase 2BiogenNCT00438607Written as BIIB014How we know
- Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male VolunteersCompletedPhase 1BiogenNCT00531193Written as BIIB014How we know
Codes
What other systems call vipadenant · ClinicalTrials.gg INT005572
- MeSH (NLM) C5472743-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) LDR3USH1NJVIPADENANTConfirmed FDA, NLM, Wikidata
- Wikidata Q27089145vipadenantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152892VipadenantOne source FDA
- DrugBank DB06625One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C547274 | 3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | LDR3USH1NJ | VIPADENANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27089145 | vipadenant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152892 | Vipadenant | One source FDA |
| DrugBank | DB06625 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.